| Date | Title | Description |
| 30.08.2026 | Catalent Completes $4.1 Billion Debt Refinancing To Cut Annual Interest Expense By $100 Million | Catalent, a global contract development and manufacturing organization, has completed a refinancing transaction to support continued growth and investments in its business. The refinancing includes a new $4.1 billion equivalent seven-year T... |
| 19.08.2026 | Pharmaceutical Contract Manufacturing Market to Reach USD 311.95 Billion by 2030 | The global Pharmaceutical Contract Manufacturing Market is projected to grow from USD 209.90 billion in 2025 to USD 311.95 billion by 2030, registering a CAGR of 8.2% during the forecast period. Growth is being driven by the increasing outs... |
| 15.07.2026 | MMJ will Stay Marijuana Rescheduling? Why the D.C. Circuit Should Halt DEA's Schedule III Order | "The government cannot tell pharmaceutical companies to follow the rules for eight years, then reward everyone who didn't. That's not reform-it's arbitrary government." - Duane Boise CEO MMJ International Holdings.
WASHINGTON, D.C... |
| 15.07.2026 | Blow-fill-seal Technology Market Forecast Signals Strong Demand for Integrated Aseptic Manufacturing | The Blow-fill-seal Technology Market size was valued at USD 386.34 Million in 2025 and the total Blow-fill-seal Technology revenue is expected to grow at a CAGR of 5.37% from 2026 to 2032, reaching nearly USD 557.18 Million.
Blow-fill-seal ... |
| 13.03.2026 | From a start-up biotech firm to a global vaccine giant | - |
| 12.01.2026 | SmartCella and Catalent sign nonexclusive license agreementfor GMP iPSCs | SmartCella and Catalent sign nonexclusive license agreementfor GMP iPSCs
Mon, Jan 12, 2026 13:00 CET Report this content
Tullinge, Sweden, and Tampa, FL, US - SmartCella Holding AB (“SmartCella”), a global biopharma company developing and m... |
| 31.10.2025 | Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by "Championing the Missions that Matter™" | TAMPA, Fla., Oct. 31, 2025 /PRNewswire/ -- Catalent, Inc., a leading global contract development and manufacturing organization, today unveiled its new corporate brand, marking a strategic evolution that underscores the company's commitment... |
| 22.10.2025 | Pharmaceutical, life science industries drive trade surge between Indiana and Portugal | Please subscribe to IBJ to decode this article.
oceaseeaaan varlteeaeenaselm f eeva.gylo tih ecucorc id srli fts ht aamTgduotfd np ioe hciin’aes wusodyeir epnlnitte r,aIih rprsssttdyinn eltt rheeogPepdftt
aaAsao orh edyi atdo.cias rhdefrc n... |
| 26.09.2025 | Catalent Announces Opening of its New Global Corporate Headquarters in Tampa, Florida | Relocation reflects a strategic expansion in Florida alongside long-standing manufacturing facility in nearby St. Petersburg
New headquarters designed to support innovation, collaboration and growth
TAMPA, Fla., Sept. 26, 2025 /PRNewswire/ ... |
| 21.08.2025 | Riding high on Wegovy, Novo doubled its workforce. Now layoffs loom | Riding high on Wegovy, Novo doubled its workforce. Now layoffs loom
By Jacob Gronholt-Pedersen and Maggie FickAugust 21, 20256:23 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Boxes of Wegovy ... |
| 04.06.2025 | Akadeum Life Sciences Raises $20M+ in Funding | Akadeum Life Sciences, an Ann Arbor, MI-based company which specializes in buoyancy-based cell separation technology, raised $20M+ in funding.
The round was led by Michigan Capital Network, with participation from Arboretum Ventures, NYBC V... |
| 14.04.2025 | OpenText Customers Leverage AI, Cloud and Security Solutions to Drive Transformation and Success | OpenText™ the leader Information Management, helps organizations solve complex global problems and impactful transformation with a comprehensive suite of Business Clouds, Business AI and Business Technology including Security. With innovati... |
| 05.03.2025 | Ascend Advanced Therapies Appoints John Chiminski as Chair and Karen Flynn as Independent Director | ROCKVILLE, Md., March 5, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), a gene to GMP advanced therapy development partner, today announced the appointment of John Chiminski and Karen Flynn as non-executive members of its Board of... |
| 16.01.2025 | Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus | Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus
By Patrick WingroveJanuary 16, 20257:24 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
A general view of the... |
| 16.12.2024 | Novo Nordisk инвестирует $1,2 млрд в новое производственное предприятие в Дании | Датский фармацевтический гигант Novo Nordisk заявил, что создаст в Оденсе производственный объект, предназначенный для выпуска различных видов продукции для лечения редких заболеваний, таких как гемофилия.
Строительные работы уже начались и... |
| 06.12.2024 | Transforming Industries: The Rise of Radiopharmaceuticals and Plastic Recycling Technologies | In the world of healthcare and environmental sustainability, two sectors are making waves: radiopharmaceuticals and plastic recycling. Both are crucial in addressing modern challenges. One focuses on healing, while the other aims to save ou... |
| 05.12.2024 | AtomVie Global Radiopharma Appoints Dr. Pratibhash Chattopadhyay as Chief Business Officer to Accelerate Growth and Strengthen Leadership | HAMILTON, ON, Dec. 5, 2024 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, is pleased to announce the appointment of Dr. Pratibhash (Bosh) Chattopadhyay as Chief Business Officer. Dr. Chattop... |
| 20.11.2024 | OpenText's AI Revolution: Transforming Enterprise Productivity | In the ever-evolving landscape of enterprise software, OpenText is carving a niche with its latest innovations. The company recently unveiled its Cloud Editions (CE) 24.4, a release that promises to elevate productivity and return on invest... |
| 19.11.2024 | OpenText expands AI capabilities to improve enterprise productivity and ROI | Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More
There is a lot of hype and a lot of promise surrounding AI and what it can bring to an enterprise. For enterprise... |
| 18.10.2024 | The Microbiome Revolution: Holobiome's $9 Million Leap Forward | In the world of health and wellness, the gut is the new frontier. Holobiome, a microbiome platform company, has just secured $9 million in a Seed funding round. This investment is not just a financial boost; it’s a signal that the microbiom... |
| 18.10.2024 | Consumer groups ask FTC to block Novo Holdings-Catalent deal | Boards, Policy & RegulationMergers & Acquisitions
Regulatory Oversight
Corporate Counsel
Health
Consumer groups ask FTC to block Novo Holdings-Catalent deal
By Jody Godoy and Maggie FickOctober 17, 20249:55 PM UTCUpdated ago
Text
Sm... |
| 10.10.2024 | US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal | Boards, Policy & RegulationGovernment
Regulatory Oversight
Mergers & Acquisitions
Health
US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
By Jody GodoyOctober 10, 20241:18 PM UTCUpdated ago
Text
Small Text
Medium... |
| 31.08.2024 | Catalent delays filing of annual report | Healthcare & PharmaceuticalsCommercial Strategy
Catalent delays filing of annual report
By ReutersAugust 30, 20249:32 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
A general view of the dr... |
| 25.07.2024 | Syngene Q1 net profit down 19% to ₹75.7 crore | Syngene International Limited, the contract research unit of Biocon, has reported a dip of 19 per cent year-on-year (Y-o-Y) in profit after tax (PAT) from ₹93.4 crore to ₹75.7 crore in the first quarter that ended June 30, 2024.
Also read: ... |
| 17.06.2024 | Lupin appoints Abdelaziz Toumi as CEO of its new subsidiary | Global pharma major Lupin has appointed Abdelaziz Toumi as the Chief Executive Officer of its newly formed subsidiary, Lupin Manufacturing Solutions (LMS).
The subsidiary is engaged in the development and sale of active pharmaceutical Ingre... |
| 24.05.2024 | Lilly invests further $5.3 bln in new Indiana site as obesity drug demand soars | Healthcare & PharmaceuticalsLilly invests further $5.3 bln in new Indiana site as obesity drug demand soars
By Patrick WingroveMay 24, 20243:32 PM UTCUpdated ago
Save
Text
Small Text
Medium Text
Large Text
Share
Twitter
Facebook
Linkedi... |
| 12.04.2024 | Healthcare M&A Volume Falls in Q1:24, According to Acquisition Data from LevinPro HC | LevinPro HC
Healthcare merger and acquisition activity declined by 4% in the first quarter of 2024, according to new acquisition data from LevinPro HC. Deal volume in Q1:24 only reached 494 deals, falling short of the 515 transactions annou... |
| 13.03.2024 | $69.7 Billion Oral Solid Dosage Contract Manufacturing Market Assessment 2024-2034 Featuring Lonza Group, Catalent, Recipharm | - |
| 13.03.2024 | Global Oral Solid Dosage Contract Manufacturing Market 2024-2030: Regional Trends for Tablets, Capsules, Powders, and Granules | - |
| 09.03.2024 | INVESTIGATION UPDATE: Halper Sadeh LLC Investigates CTLT, EVBG, FREE, KNTE | - |
| 07.03.2024 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT | - |
| 07.03.2024 | Clinical Trial Supply and Logistics Market Sees Promising Growth as Demand for Personalized Medicine Surges | - |
| 04.03.2024 | Pharmaceutical Manufacturing Market Projected to Grow at 7.8% CAGR, Reaching $863.6 Bn by 2030 | Vantage Market Research | Vantage Market Research
Pharmaceutical Manufacturing Market Size, Share, Industry Trends, Growth, and Opportunities Analysis by 2030 WASHINGTON, D.C, DISTRICT OF COLUMBIA, UNITED STATES, March 4, 2024 /EINPresswire.com/ -- The Global Pharma... |
| 07.02.2024 | Catalent Japan Co., Ltd. Regarding support for damage caused by the 2020 Noto Peninsula Earthquake | - |
| 07.02.2024 | Catalent Japan Co., Ltd. Regarding support for damage caused by the 2020 Noto Peninsula Earthquake | Catalent Japan Co., Ltd.
Regarding support for damage caused by the 2020 Noto Peninsula Earthquake ……
Catalent Japan Co., Ltd. (Headquarters: Minato-ku, Tokyo) would like to express our deepest condolences to those who lost their lives in t... |
| 05.02.2024 | Novo Holdings to Acquire Catalent | Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, acquired Catalent, Inc. (NYSE: CTLT), a Somerset, NJ-based leader in enabling the development and supply ... |
| 08.06.2023 | Catalent and JLABS Symposium to Discuss Accelerated Development and Manufacturing of Biologics | SOMERSET, N.J. (PRWEB) June 08, 2023
The Catalent Applied Drug Delivery Institute, which was established as a cross-industry consortium to accelerate the adoption of advanced drug delivery technologies, today announced that it will hold a s... |
| 05.06.2023 | Catalent Expands OneBio® Suite for Integrated Development, Manufacturing and Supply Across Biologic Modalities | Since its launch, we have been able to demonstrate how beneficial the OneBio integrated biologics development solution can be to sponsors, saving them time on managing multiple partners, and handoffs between companies.
SOMERSET, N.J. (PRWEB... |
| 25.05.2023 | Catalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell and Gene Therapy Development | Catalent's Clinical Supply Facility in Shiga, Japan The market in Japan for advanced therapies and new modalities continues to grow, along with the demand for companies such as Catalent that have the advanced infrastructure to handle the su... |
| 25.05.2023 | Catalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell and Gene Therapy Development | SOMERSET, N.J., May 25, 2023 /PRNewswire/ -- Catalent (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has expanded the services and capabilities at its faci... |
| 16.05.2023 | Catalent to Present on Integrated UpTempoSM Gene Therapy Development Platform at Upcoming ASGCT Annual Meeting | SOMERSET, N.J. (PRWEB) May 16, 2023
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that George Buchman, Ph.D., Vice President, Pre-Clinical and Process Development, w... |
| 20.04.2023 | Catalent Chief Scientific Officer to Present at Upcoming Symposium of the International Consortium for Advanced Medicines Manufacturing | SOMERSET, N.J. (PRWEB) April 20, 2023
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that its Vice President & Chief Scientific Officer, Julien Meissonnier, will ... |
| 13.04.2023 | Catalent Experts to Co-Host Workshops on Supply Chain Management at Upcoming Global Clinical Supplies Group Conference | SOMERSET, N.J. (PRWEB) April 13, 2023
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that two of its clinical supply experts are to co-host workshop sessions at the u... |
| 06.04.2023 | Catalent Commences Construction of New $20M Expansion to its Clinical Supply Facility in Schorndorf, Germany | Our site in Schorndorf plays a key strategic role in our global clinical supply network, and this expansion will provide much needed capacity and capabilities to meet the growing needs of customers.
SOMERSET, N.J. (PRWEB) April 06, 2023
Cat... |
| 30.03.2023 | Accelerated Development and Manufacturing of Oral Small Molecules to be Discussed by Catalent Applied Drug Delivery Institute and JLABS | SOMERSET, N.J. (PRWEB) March 30, 2023
The Catalent Applied Drug Delivery Institute, which was established as a cross-industry consortium to accelerate the adoption of advanced drug delivery technologies, today announced that it will hold a ... |
| 29.03.2023 | Catalent Launches New Oral Developability Assessment and Manufacturing Solution to Advance Targeted Protein Degrader Programs | Targeted protein degraders have the potential to revolutionize new small molecule therapies, but if they are to be successful oral treatments, they require a rational approach to development and a comprehensive toolkit of proven technologie... |
| 23.03.2023 | Harm Reduction Therapeutics and Catalent Sign Commercial Supply Agreement for Naloxone Nasal Spray to Reverse Opioid Overdoses | Our company is driven by a ‘patient-first’ culture, which is synergistic with the goals and mission of our partner on this project, and we take great pride in being associated with such a potentially life-changing program.
PITTSBURGH, PA an... |
| 16.03.2023 | Catalent and Bhami Research Laboratory Enter into Licensing Agreement for Technology to Deliver High-Concentration Biologics Subcutaneously | The potential for maintaining the stability of a drug with the convenience of a pre-filled syringe or auto-injector could have a significant impact on reducing the barriers to subcutaneous delivery of therapies and improving the patient exp... |
| 15.03.2023 | Catalent and Grünenthal Announce Successful Collaboration to Facilitate Expedited Clinical Development Timelines | Working with Grünenthal, we have been able to leverage multiple services that have not only reduced Phase 1 development timelines substantially, but have done so using a formulation and delivery technology that is scalable for future clinic... |
| 09.03.2023 | Catalent Expands UpTempo ℠ AAV Platform to Accelerate Development of Gene Therapies | Having a partner that offers end-to-end solutions provides security of supply, can eliminate time-consuming tech transfers between companies, optimizes the development steps, and ensures seamless transition from development through to comme... |
| 02.03.2023 | Catalent Expert to Chair Panel Discussion on Integrated Clinical Drug Development Partnerships at Upcoming Bio Supply Management Alliance Conference | SOMERSET, N.J. (PRWEB) March 02, 2023
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that its Vice President of Business Transformation and Regional General Manager, ... |
| 16.02.2023 | Catalent Expert to Discuss Supply Strategies at Upcoming Clinical Outsourcing Group Conference | SOMERSET, N.J. (PRWEB) February 16, 2023
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that its Global Director of Clinical Supply Management, Stephanie Graham, is t... |
| 14.02.2023 | Catalent Completes Expansion of Singapore Clinical Supply Facility for Increased Temperature-Controlled Capabilities | The Singapore site was the first Catalent clinical supply facility in the Asia-Pacific region, and now serves as a strategic supply hub, shipping clinical materials with high reliability and speed to over 20 countries.
SOMERSET, N.J. (PRWEB... |
| 26.01.2023 | Catalent Completes Commercial-Scale Plasmid DNA Manufacturing Facility in Gosselies, Belgium | Plasmid DNA is a critical component to many biological therapeutics, and Catalent has made this investment in additional manufacturing capacity in anticipation of supporting the growing number of programs through development towards commerc... |
| 24.01.2023 | Catalent Launches New Service for End-to-End Supply Chain Case Management of Cell and Gene Therapies | The Case Management Service enables customers, who are often resource-constrained, to focus their resources on the science and development of advanced therapies, and allow highly experienced specialists to manage the complex and highly time... |
| 12.01.2023 | Catalent and Ethicann Sign Development and License Agreement for New Fast-Dissolve Cannabinoid-Based Treatments | Zydis can be used to rapidly administer therapeutic doses of active drug, and we look forward to continuing the relationship and applying all our expertise in developing, launching and supplying new differentiated therapies with the potenti... |
| 14.12.2022 | Catalent to Expand Its Biologics Analytical Services with New Facility in Durham, North Carolina | Catalent is committed to the continuous growth and expansion of its analytical capabilities to provide extensive CMC support and solutions that are compliant with current good laboratory and manufacturing practices.
SOMERSET, N.J. (PRWEB) D... |
| 08.12.2022 | Catalent Opens One of the World’s Largest Commercial-Scale Cell Therapy Manufacturing Facilities at its European Center of Excellence in Gosselies, Belgium | Catalent enables fully integrated cell therapy services — from our iPSC expertise in Düsseldorf, Germany, to process and analytical development in Gosselies, to clinical and commercial manufacturing in Gosselies and Princeton, New Jersey — ... |
| 01.12.2022 | Catalent Completes Expansion of Clinical Supply Facility in Shanghai, China | Catalent's clinical supply facility in the Waigaoqiao Free Trade Zone in Shanghai, China China is the fastest growing clinical trials market in the Asia-Pacific region, and... these additional capabilities increase the site’s ability to sup... |
| 20.10.2022 | Catalent Expands Biologics Analytical Capabilities with New Laboratories at Center of Excellence in Kansas City, Missouri | Catalent's facility in Kansas City, Missouri Our team at Kansas City serves as a strategic partner for customers of all sizes, and this expansion will allow it to support the increased demand and assay requirements for broad-based and ortho... |
| 21.09.2022 | Why it's easier to find Pfizer's updated COVID boosters than Moderna's | Vaccinators around the country are reporting weeks-long delays in shipments of Moderna's updated COVID-19 vaccine boosters. The delays come after the Food and Drug Administration flagged concerns at a facility contracted to fill the Moderna... |
| 19.09.2022 | Catalent Appoints Karen Santiago as Vice President and Chief Accounting Officer | Karen's extensive background and deep finance expertise make her a valued addition to the team.
SOMERSET, N.J. (PRWEB) September 19, 2022
Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimiz... |
| 08.09.2022 | Catalent Appoints Dr. Wai Lam Ling as Vice President, Scientific Advisory | Wai Lam Ling, Vice President, Scientific Advisory at Catalent We welcome Wai Lam to Catalent, where she will have a pivotal role in leading the company’s scientific advisory team of experts to help innovators, which is unique in our industr... |
| 08.09.2022 | Manufacturing roundup: Catalent expands in Singapore; Cambrex completes first phase of $30M NC expansion | Catalent is looking to expand its clinical supply facility in Singapore.
The $2.2 million investment will grow the facility by 31,000 square feet to allow for 35 new freezers to be installed for more ultra-low tempera... |
| 06.09.2022 | Catalent Expands Singapore Clinical Supply Facility for Increased Temperature-Controlled Capabilities | Our Singapore site serves as a strategic supply hub for the Asia-Pacific market, offering a wide range of services to customers in over 20 countries in the region
SOMERSET, N.J. (PRWEB) September 06, 2022
Catalent, the global leader in enab... |
| 07.07.2022 | Manufacturing roundup: WuXi continues its expansion drive with another plant opening in Changzhou; Swiss biotech nets another acquisition | A Catalent site outside of BWI Airport in Baltimore is getting an upgrade.
The Somerset, NJ-based manufacturer will pump $230 million into the site in order to add three more viral vector manufacturing suites and associated services in Harm... |
| 30.06.2022 | Catalent Expands Primary Packaging Capabilities at its Clinical Supply Facility in Shiga, Japan | Catalent Facility in Shiga, Japan Shiga is a key hub within our Asia-Pacific clinical supply services network, and with these new capabilities, which are now fully operational, we will offer a comprehensive range of services, which are cust... |
| 16.06.2022 | Catalent Experts to Discuss Managing Successful Direct-to-Patient Clinical Supplies and Overcoming Product Launch Challenges at Upcoming BSMA Conference | SOMERSET, N.J. (PRWEB) June 16, 2022
Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today annou... |
| 09.06.2022 | Catalent Supports U.S. Launch of Phathom Pharmaceuticals’ New Products Following Regulatory Approval | Catalent's flagship U.S. manufacturing facility for large scale oral dose forms in Winchester, Kentucky, which has recently undergone a $175-million expansion. Catalent's Winchester team has an extensive history of supporting product launch... |
| 07.06.2022 | Catalent and MigVax Sign Agreement to Develop an Orally Disintegrating Freeze-Dried Tablet Vaccine Against COVID-19 | Catalent's Zydis® orally disintegrating tablet (ODT) technology Once our vaccine can be transported using the Zydis Bio technology, in unrefrigerated vehicles and stored in standard warehouses, it will be much easier and cost-effective for ... |
| 19.05.2022 | Catalent introduces new AAV gene therapy tech in aim to speed up manufacturing process | As Catalent ventures further into the world of cell and gene therapy manufacturing, the New Jersey-based CDMO has revealed its new adeno-associated viral vector platform.
The UpTempo Virtuoso platform can streamli... |
| 19.05.2022 | Catalent Invests $175 Million to Expand Manufacturing Capabilities and Capacity at Winchester, Kentucky | Catalent's Winchester Facility Our Winchester site has a rich history in the successful commercialization of new products, and this expansion is the latest in a series of strategic investments, totaling hundreds of millions of dollars, to e... |
| 16.05.2022 | Catalent Launches UpTempo Virtuoso™ AAV Platform to Reduce Gene Therapy Development Time and Accelerate Path to Clinic | As the gene therapy pipeline expands...and in anticipation of rising regulatory requirements, our optimized and standardized CGMP manufacturing process is designed to meet robust CMC submissions for AAV gene therapy products, while providin... |
| 28.04.2022 | Catalent Expands Nasal Drug Development and Manufacturing Capabilities at Morrisville, North Carolina, Facility | New state-of-the-art high-speed filling line at Catalent’s facility in Morrisville, RTP (courtesy of Dara Pharmaceutical Equipment) Our team in Morrisville has a long history of success in developing and commercializing nasal drug products,... |
| 25.04.2022 | Catalent Acquires Commercial-Scale Cell Therapy Development and Manufacturing Facility in Princeton, New Jersey, from Erytech | The Princeton facility that Catalent has acquired from Erytech Pharma This acquisition is strategically important to Catalent’s commitment to support the development and clinical and commercial supply of cell therapies to meet rapidly growi... |
| 21.04.2022 | Catalent to Invest $350 Million in Integrated Biologics Drug Substance and Drug Product Manufacturing at Bloomington, Indiana, Facility | The Catalent Biologics facility in Bloomington, Indiana, where the company will add to its drug substance and drug product capabilities These investments will enable us to expand our flagship Bloomington facility and extend our leadership a... |
| 21.04.2022 | Synthetic biology biotech nets three-hit combo in new financing, Bristol Myers deal and first CSO | A Bay Area biotech announced three new developments that have been in the works in recent months, hoping that all have a strong chance at propelling the company forward.
The first and newest development is the financing, as O... |
| 21.04.2022 | Catalent drops $350M to expand Indiana site that includes Moderna-dedicated line | Bloomington, IN, is the home of Indiana Hoosiers basketball – and the center of Catalent’s biologics drug substance manufacturing operations. And while the university’s forward Trayce Jackson-Davis might be leaving ... |
| 21.04.2022 | Drugs containing nanomaterials: FDA finalizes 2017 guidance with several changes | The FDA on Thursday finalized a draft guidance from 2017 explaining the principles and specific considerations for developing drugs (biologics and gene therapies are excluded) containing nanomaterials, includ... |
| 21.04.2022 | FDA's ODAC votes unanimously that future PI3K inhibitors should include randomized data for blood cancers | A fledgling New York biotech has managed to catch the eye of Sanofi, signing a new collaboration with the pharma giant to acquire two of its programs — but giving away few other details.
Terran Biosciences announced the deal in a short pres... |
| 21.04.2022 | How Novartis assesses a drug's probability of success prior to the pivotal trial | Transitioning a developing compound from early phase clinical trials to a pivotal trial(s) can be a make-or-break decision for a small- or medium-sized pharma. And sometimes companies aren’t very good at making the righ... |
| 21.04.2022 | Orasis will ship its Vuity eye drop competitor to the FDA later this year with two PhIII wins | Orasis Pharmaceuticals probably doesn’t think it’s the underdog with the two Phase III results it has in hand for an eye drop meant to help people with age-related loss of near vision.
But once the Florida biotech ships the e... |
| 21.04.2022 | Another new manufacturing site for NC; BioCentriq acquired by South Korean company | Enzyvant will expand its regenerative medicine manufacturing with a new facility in North Carolina’s Research Triangle Park area.
The building of the 25,972-square-foot site will start this summer and wrap up around t... |
| 19.04.2022 | Catalent Experts to Discuss Improving Clinical Supply Chain Efficiency and Future Workforce Strategies at Upcoming GCSG Conference | SOMERSET, N.J. (PRWEB) April 19, 2022
Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today anno... |
| 14.04.2022 | Catalent Adds New High-Throughput Encapsulation Manufacturing Suites at Kansas City, Missouri, Facility | The Kansas City site is an integral part of Catalent’s global manufacturing network for oral solid dose forms, and this latest expansion reflects the growth in demand for specialist products.
SOMERSET, N.J. (PRWEB) April 14, 2022
Catalent, ... |
| 06.04.2022 | Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK and Across Europe | VMIC facility at Harwell Science and Innovation Campus, UK This acquisition allows Catalent to collaborate with the rich academic and biomedical science community centered around Oxford, with its world-class talent, and will result in a fac... |
| 06.04.2022 | Catalent wins bidding war to take on UK's VMIC | When a source from the UK government talked to the Financial Times back in December about the potential sale of a ready-made vaccine manufacturing site, one thing was made clear: Stakeholders wanted to sell it to “someone w... |
| 17.03.2022 | Catalent Appoints Frederic Cedrone as Vice President, Corporate Innovation | Frederic Cedrone, Ph.D, Catalent's Vice President, Corporate Innovation Catalent has a proud history of building collaborative partnerships with innovators, academic institutions and industry specialists, and through these, we have been abl... |
| 16.03.2022 | Catalent Biologics Completes $30 Million Project for Biopharmaceutical Development and Drug Product Manufacturing in Limoges, France | This investment has transformed the Limoges site into a world-class facility to support the development of early phase and small-scale commercial biologic drugs, and offers customers integrated services to accelerate programs towards and th... |
| 10.03.2022 | KELIX acquires Moroccan manufacturer; Sustainability and charity focus of Catalent's corporate responsibility report | A biopharma manufacturer in Dubai has acquired PHI, a leading pharma manufacturer in Morocco, as a part of a larger plan to provide health coverage for the country’s residents. KELIX bio will use the purchase to acc... |
| 03.03.2022 | NIH offers to share Covid-19 technologies with WHO — report | In what may be a first for the US government, the Biden administration is expected to share Covid-19 technologies developed by the NIH with the WHO’s Covid-19 Technology Access Pool, or C-TAP.
The move would allow other countries to replica... |
| 03.03.2022 | After 25 years, Hovione's CEO will step down; Helsinn gains infigratinib license from BridgeBio | Hovione’s current COO will become its CEO on April 1.
The company announced that Guy Villax, the CEO for 25 years, will step down from his role. He will transition to the role of board member and shareholder. The company grew 10-fold in his... |
| 03.03.2022 | Catalent Experts to Discuss Evolving Strategies for Flexible, Dynamic and Resilient Clinical Supply at Upcoming Conferences | SOMERSET, N.J. (PRWEB) March 03, 2022
Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today anno... |
| 03.03.2022 | Covid-19 manufacturing roundup: 9 partners to help Biovac's manufacturing expansion; After production pledges, Covid-19 test demand has plummeted | A consortium of nine partners will support Biovac’s expansion of its South African manufacturing plant capacity in an effort to boost production of the Pfizer-BioNTech Covid-19 vaccine.
Biovac will raise about $150 million to boost local ca... |
| 03.03.2022 | Catalent expands inhalation efforts in collaboration with Texas-based pharma | TFF Pharmaceuticals is on the hunt for new partners, and a recently-announced agreement with Catalent could help them land just that.
The two companies announced a collaboration focused on the generation, testing and manufacture of dry powd... |
| 15.02.2022 | Catalent expands deep-freeze operations in Chinese free trade zone | As the world watches the Winter Olympic Games wrap up the final week in Beijing, a Catalent site 750 miles away from the Olympic Village is getting its own deep freeze award. The Waigaoqiao Free Trade Zone facility is getting an upgrade to ... |
| 15.02.2022 | AstraZeneca/Merck come out of ASCO GU with a big win over J&J in battle over prostate cancer franchises | Amgen once again finds itself touting KRAS G12C data that don’t measure up to a rival at Mirati, as the smaller player struggles to play catch-up.
After the market closed on Monday, the pharma giant posted a set of new data from their Lumak... |
| 15.02.2022 | AstraZeneca/Merck come out of ASCO GU with a big win over J&J in battle over prostate cancer franchises | Cytokinetics’ relentless quest to demonstrate that its heart drug omecamtiv has real value ran into another thicket of bad data Tuesday morning.
The biotech reported that its Phase III METEORIC study had flat failed to demonstrate an improv... |
| 15.02.2022 | Catalent Expands Temperature-Controlled Clinical Supply Capabilities in Shanghai, China | Catalent's Waigaoqiao Free Trade Zone (FTZ) facility in Shanghai, China This expansion will increase both capacity and capabilities at the Shanghai FTZ facility, and makes provision for the growing trend in clinical trials of advanced thera... |
| 15.02.2022 | Catalent : Expands Temperature-Controlled Clinical Supply Capabilities in Shanghai, China | SOMERSET, N.J. - February 15, 2022 - Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today anno... |
